PMV Pharmaceuticals (NASDAQ:PMVP) Announces Earnings Results, Misses Expectations By $0.08 EPS

PMV Pharmaceuticals (NASDAQ:PMVP) posted its earnings results on Monday. The company reported ($0.45) EPS for the quarter, missing the consensus estimate of ($0.37) by ($0.08), Zacks reports.

PMV Pharmaceuticals Price Performance

Shares of PMVP opened at $1.29 on Wednesday. The company has a market capitalization of $66.75 million, a PE ratio of -1.29 and a beta of 1.46. PMV Pharmaceuticals has a one year low of $1.23 and a one year high of $2.26. The company’s fifty day moving average price is $1.43 and its 200 day moving average price is $1.52.

Analyst Ratings Changes

Separately, Oppenheimer raised PMV Pharmaceuticals from a “market perform” rating to an “outperform” rating and set a $6.00 price objective on the stock in a report on Friday, November 8th. Four analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $5.50.

PMV Pharmaceuticals Company Profile

PMV Pharmaceuticals, Inc, a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It's lead product candidate is PC14586, a small molecule that corrects mutant p53 protein containing the Y220C mutation and restores wild-type p53 function.